Physician profile
Rahul R Naik
NPI 1992999031
$296,815.31
in general payments reported to CMS, 2019-2025
77 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $29K · 2021: $21K · 2022: $72K · 2023: $61K · 2024: $36K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $75K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $14K · Food and Beverage: $14K · Travel and Lodging: $13K · Education: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $74,510.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,317.50 |
| Consulting Fee | $14,460.00 |
| Food and Beverage | $13,622.83 |
| Travel and Lodging | $12,561.89 |
| Education | $441.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $140,590.08 | 2020-2025 | Xpovio |
| Incyte Corporation | $55,244.70 | 2019-2024 | Jakafi, Pemazyre, Monjuvi |
| Pfizer INC. | $25,625.82 | 2019-2025 | |
| Glaxosmithkline, LLC. | $22,259.62 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Celgene Corporation | $14,968.19 | 2019-2025 | Reblozyl, Opdualag |
| Bayer Healthcare Pharmaceuticals INC. | $5,964.50 | 2019-2025 | |
| Astellas Pharma US INC | $4,575.00 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Eisai INC. | $4,038.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $3,319.85 | 2019-2025 | Lynparza, Enhertu, Calquence |
| Exelixis INC. | $3,097.52 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $2,761.33 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $2,223.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,075.98 | 2019-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $781.29 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Merck Sharp & Dohme LLC | $746.97 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $571.97 | 2019-2023 | Lumakras, Kyprolis, Blincyto |
| Lilly USA, LLC | $564.00 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.10 | 2019-2025 | |
| Gilead Sciences, INC. | $514.25 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $472.42 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Emd Serono, INC. | $441.17 | 2020-2025 | Bavencio |
| Puma Biotechnology, INC. | $417.36 | 2019-2025 | Nerlynx |
| Sun Pharmaceutical Industries INC. | $335.26 | 2019-2025 | Yonsa |
| Sobi, INC | $315.29 | 2024-2025 | |
| Array Biopharma INC | $314.82 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Daiichi Sankyo INC. | $293.25 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Pharmaessentia USA Corporation | $283.01 | 2022-2025 | Besremi |
| Seagen INC. | $268.20 | 2021-2024 | Tukysa, Tivdak |
| Alnylam Pharmaceuticals INC. | $238.87 | 2023-2025 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $203.48 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $201.30 | 2021-2025 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Alexion Pharmaceuticals, INC. | $192.75 | 2019-2025 | Ultomiris |
| Myovant Sciences INC. | $192.11 | 2021-2022 | |
| Clovis Oncology, INC. | $173.16 | 2019-2022 | |
| Tesaro, INC. | $162.32 | 2019 | |
| Blueprint Medicines Corporation | $161.09 | 2022-2025 | Ayvakit |
| Agios Pharmaceuticals, INC. | $146.63 | 2023-2025 | Pyrukynd |
| Genzyme Corporation | $144.58 | 2021-2025 | |
| Taiho Oncology, INC. | $140.77 | 2023-2025 | |
| Stemline Therapeutics INC. | $135.85 | 2023-2025 | Orserdu, Elzonris |
| Rigel Pharmaceuticals, INC. | $124.55 | 2019-2022 | |
| Abbvie INC. | $119.51 | 2019-2025 | |
| Secura Bio, INC. | $118.32 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $116.23 | 2022-2024 | Fotivda |
| Tersera Therapeutics LLC | $99.83 | 2021-2025 | Zoladex |
| Legend Biotech USA INC. | $96.92 | 2025 | Carvykti |
| Adc Therapeutics America, INC. | $88.82 | 2023-2024 | |
| Global Blood Therapeutics, INC. | $88.15 | 2021-2022 | |
| Mirati Therapeutics, INC. | $85.99 | 2023-2024 | Krazati |
| Deciphera Pharmaceuticals INC. | $73.05 | 2024-2025 | Qinlock, Tgct |
| Kite Pharma, INC. | $73.00 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $72.86 | 2023 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $67.60 | 2020-2021 | |
| Beigene USA, INC. | $58.30 | 2022-2023 | Brukinsa |
| Kyowa Kirin, INC. | $56.44 | 2023-2024 | Poteligeo |
| Dova Pharmaceuticals | $54.17 | 2019-2021 | |
| Syndax Pharmaceuticals, INC. | $45.12 | 2025 | |
| Acrotech Biopharma INC. | $41.90 | 2021 | |
| Adaptive Biotechnologies Corporation | $41.02 | 2024 | Clonoseq |
| Octapharma USA, INC. | $34.70 | 2025 | Panzyga |
| Verastem, INC. | $32.14 | 2019 | |
| Myriad Genetic Laboratories, INC. | $29.08 | 2022 | |
| Novocure INC. | $28.71 | 2024 | Optune Lua (Novottf-200t) |
| Coherus Oncology, INC. | $28.54 | 2023-2024 | |
| Blue Earth Diagnostics | $27.65 | 2024 | |
| Cti Biopharma Corp. | $26.79 | 2023 | Vonjo |
| Azurity Pharmaceuticals, INC. | $25.98 | 2025 | Vivimusta, Danziten |
| Epizyme, INC. | $25.42 | 2020 | |
| Morphosys, US INC. | $22.96 | 2023 | Monjuvi |
| Accord Healthcare, INC. | $22.41 | 2024 | |
| Verity Pharmaceuticals INC. | $22.09 | 2022 | |
| Beone Medicines USA, INC. | $21.22 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $19.47 | 2023 | Imbruvica |
| Immunogen, INC. | $16.56 | 2023 | Elahere |
| Teva Pharmaceuticals USA, INC. | $13.52 | 2019 | |
| Eusa Pharma (US) LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Naik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.